Matrix metalloproteinase 9 (MMP9) is involved in the proteolysis of extracellular proteins and plays a critical role in pancreatic ductal adenocarcinoma (PDAC) progression, invasion and metastasis. The therapeutic potential of an anti-MMP9 antibody (αMMP9) was evaluated in combination with nab-paclitaxel (NPT)-based standard cytotoxic therapy in pre-clinical models of PDAC. Tumour progression and survival studies were performed in NOD/SCID mice. The mechanistic evaluation involved RNA-Seq, Luminex, IHC and Immunoblot analyses of tumour samples. Median animal survival compared to controls was significantly increased after 2-week therapy with NPT (59%), Gem (29%) and NPT+Gem (76%). Addition of αMMP9 antibody exhibited further extension in survival: NPT+αMMP9 (76%), Gem+αMMP9 (47%) and NPT+Gem+αMMP9 (94%). Six-week maintenance therapy revealed that median animal survival was significantly increased after NPT+Gem (186%) and further improved by the addition of αMMP9 antibody (218%). Qualitative assessment of mice exhibited that αMMP9 therapy led to a reduction in jaundice, bloody ascites and metastatic burden. Anti-MMP9 antibody increased the levels of tumour-associated IL-28 (1.5-fold) and decreased stromal markers (collagen I, αSMA) and the EMT marker vimentin. Subcutaneous tumours revealed low but detectable levels of MMP9 in all therapy groups but no difference in MMP9 expression. Anti-MMP9 antibody monotherapy resulted in more gene expression changes in the mouse stroma compared to the human tumour compartment. These findings suggest that anti-MMP9 antibody can exert specific stroma-directed effects that could be exploited in combination with currently used cytotoxics to improve clinical PDAC therapy. 
PDAC is in part related to the absence of early diagnostic markers, aggressive progression pattern and lack of effective therapeutic options. While surgical resection remains the only curative treatment option for PDAC, unfortunately, only 15%-20% of patients are candidates for resection, and most resected PDAC patients succumb to disease recurrence. 3 Therefore, in recent years, much attention has been placed on improving systemic therapy options for PDAC.
Gemcitabine (Gem), a nucleoside pyrimidine analogue, became the standard drug in PDAC after a positive clinical trial in 1997; it demonstrated a 5%-10% response rate and a median overall survival of 6 months. 4 FOLFIRINOX treatment, a combination of three chemotherapy drugs, nearly doubled the overall patient survival, but this regimen has higher toxicity risks. 5 Nab-paclitaxel (NPT) in combination with gemcitabine (Gem) is currently the most widely used chemotherapy regimen due to its favourable toxicity profile and median overall survival 8.5 months. 6 Due to these limitations of current regimens for clinical PDAC therapy, there is an urgent requirement for novel therapeutic strategies with better efficacy and less toxicity.
Matrix metalloproteinases (MMPs) are a family of zinc-containing enzymes that degrade extracellular matrix (ECM) components and play a crucial role in tumour invasion, metastasis and angiogenesis. 7 MMPs comprise a large family of 23 members that can be subclassified into different groups mainly based on their substrate specificity and amino acid sequence including collagenases response in pre-clinical pancreatic cancer models. 11 However, in clinical studies, the broad-spectrum MMP inhibitors marimastat or tanomastat failed to show any significant clinical response. 12, 13 The failure of the broad-spectrum MMP9 inhibitors in clinical trials was mainly correlated with dose-limiting side effects, a narrow therapeutic window as MMPs play a critical role in homeostatic processes 14 and general lack of efficacy in advanced tumour burden settings. 15, 16 Therefore, recently, the focus has been shifted towards more specific MMP inhibitors (such as MMP2 or 9 antibodies) that may have better efficacy and improved toxicity profile.
Matrix metalloproteinase 9 (MMP9) is one of the type IV collagenases of the MMP family that is capable of cleaving a wide range of ECM components including gelatins, denatured collagens, elastin and laminin. 17 MMP9 is involved in many developmental processes, including ECM degradation, angiogenesis and wound healing.
Recently, MMP9 has also been shown to be involved in cell proliferation, migration, invasion and epithelial-mesenchymal transition (EMT). 18 MMP9 overexpression has been observed in many solid tumours, including pancreatic cancer, and is correlated with poor prognosis. [19] [20] [21] [22] [23] [24] [25] In the present study, we evaluated the therapeutic efficacy of a highly selective and potent anti-MMP9 antibody AB0046, 
| Immunoblot analysis
Tumours obtained from intraperitoneal or subcutaneous xenografts were sectioned, snap frozen in liquid nitrogen and stored at −80°C.
Protein lysates of these tumour sections were prepared by suspending in lysis buffer and homogenizing using the Bullet Blender Protein bands were visualized with an Image360 system after using the enhanced chemiluminescence reagent (SignalFire, Cell Signaling) and quantitated by densitometry.
| Immunohistochemistry and immunofluorescence
Standard immunohistochemistry protocol was followed to stain the tumour tissue sections, as previously described. 28 Briefly, tumour tissues fixed in 4% paraformaldehyde were dehydrated in a graded series of ethanol and deparaffinized with xylene. The tumour tissues were then embedded in paraffin and cut into 5 μm sections using microtome. The tumour tissue sections were then deparaffinized and rehydrated through graded ethanol followed by heat-mediated antigen retrieval using citrate buffer. 
| Luminex assay
Protein analysis of tumour samples from the intraperitoneal xenografts was performed by Luminex assay. Briefly, lysates were pre- 
| RNA-Seq analysis
Gene expression changes in different therapy groups were determined by RNA sequencing (RNA-Seq) of tumour samples from subcutaneous xenografts. RNA samples isolated from frozen tumours using a Qiagen RNAeasy kit (Qiagen, Germantown, MD) were converted into cDNA libraries using the Illumina TruSeq Stranded mRNA sample preparation kit (Illumina #RS-122-2103, San Diego, CA), and RNA-Seq was performed (Q2 Solutions, Morrisville, NC). The raw fastq files were first run through FastQC to verify the data were of high quality and processed using the Expression analysis mRNAv9-RSEM pipeline. After removing sequencing adapters and other low-quality bases, the clipped fastq files were aligned to the mouse reference genome (build GRCm38) using STAR v2.4. The resulting BAM files were fed into the quantification software, RSEM v1.2.14.
RSEM output the counts of the sequencing reads for each gene and sample. After normalization, we performed quality control analyses of QC'd, the data set to identify strong batch effects and outlier samples using principal component analysis and sample dendrogram. Genes with <1 sequencing read count/106 (CPM) in ≥3 samples were removed as low count genes. Generalized linear regression in edgeR was used to estimate log2 fold changes and P values. The P values were adjusted using the false discovery rate control by following the Benjamini-Hochberg procedure. Next, the estimated P values of all the genes were converted to z scores using the zScores function in the R package gCMAP. The z scores were used to rank the list of genes, which was analysed with GSEAPreranked included in the Broad GSEA Java tool for Gene set enrichment analysis against MSigDB, C2 (curated gene sets), C6 (oncogenic signatures) and C7
(immunologic signatures) collections.
| Subcutaneous xenograft studies
All animals were housed in a pathogen-free facility with access to 
| Peritoneal dissemination animal studies
Animal survival studies were performed with female NOD/SCID mice (4-6 weeks of age) as previously described. 30 Briefly, the mice were injected intraperitoneally with AsPC-1 cells (0.75 × 10 6 or 0.65 × 10 6 ) and 2 weeks after tumour cell injection, mice were randomized (n = 5-7 per group) to receive PBS (control), nab-paclitaxel (5 mg/kg, twice a week), gemcitabine (50 mg/kg, twice a week) and anti-MMP9 antibody (50 mg/kg bolus dose on day 1, then 20 mg/kg twice a week) via IP injection for the next 2 or 6 weeks. Animals were killed when moribund according to predefined criteria. 31, 32 Animal survival was evaluated from the first day of treatment until death.
For qualitative assessment of mice in the peritoneal dissemination xenograft study, five mice in each therapy group were evaluated for jaundice, ascites, tumour burden and metastasis when control mice became moribund. The tumours obtained from these mice were processed for Luminex, IHC and Immunoblot analysis.
| Statistical analysis
Statistical analysis for in vivo tumour growth studies was performed size of 40% or more and a standard deviation of 20%, the expected power was more than 80% to detect statistically significant differences. Luminex assay data were analysed using unpaired t test with Welch's correction or Mann-Whitney rank sum tests (GraphPad Prism). P < 0.05 was considered statistically significant.
| RE SULTS

| Improvement in animal survival
In an AsPC-1 PDAC peritoneal dissemination xenograft study with No significant change in the bodyweight of mice was observed during 2 or 6-week therapy period, indicating that there was no discernable therapy-associated toxicity in all therapy groups.
| Qualitative assessment of tumourassociated aspects
In an AsPC-1 PDAC peritoneal dissemination xenograft study with 2-week therapy schedule, qualitative assessment of mice in all therapy groups was performed when control mice became moribund.
Evaluation of different tumour-associated findings revealed that compared with controls, NPT+Gem therapy led to a significant reduction in all aspects observed including jaundice, amount of ascites, tumour burden in the pancreas, tumour burden in the stomach, total tumour weight, liver metastasis, spleen metastasis and total metastatic burden. Anti-MMP9 antibody therapy significantly decreased ascites, tumour burden in pancreas and stomach, liver metastasis, spleen metastasis and total metastatic burden, as compared with controls.
However, most of the findings after NPT+Gem+αMMP9 therapy were not significantly different from those after NPT+Gem therapy alone, except a decrease in tumour burden in the pancreas (Figure 2 ).
| Changes in protein expression in tumours from intraperitoneal xenografts
Luminex analysis of cytokine or growth factor expression in tu- Two weeks after tumour cell injection in NOD/SCID mice, treatment was started with nab-paclitaxel, gemcitabine and anti-MMP9 antibody for 2 wk or 6 wk as specified. The curve represents the animal survival time from the beginning of therapy. Statistical group differences in survival time were calculated using logrank testing IL-1B and GM-CSF. An increase in IL28 expression (1.5-fold, P = 0.016) was specifically related to anti-MMP9 antibody therapy as it was significantly higher after both αMMP9 monotherapy and 
| Gene expression changes in the tumour microenvironment in subcutaneous xenografts
In an AsPC-1 subcutaneous xenograft study, compared with controls, mean tumour weight after 2-week therapy decreased by 50%
with NPT+Gem (P = 0.001), 20% with αMMP9 (P = 0.136) and 63%
with NPT+Gem+αMMP9 (P = 0.0006) ( Figure 6A ). The difference in tumour weight between NPT+Gem and NPT+Gem+αMMP9 did not reach statistical significance ( Figure 6A ). Tumour tissues from these subcutaneous xenografts revealed low but detectable levels of MMP9 protein in all therapy groups without any significant difference in MMP9 expression ( Figure 6B ). In addition, RNA-Seq analysis to determine numeric gene expression changes in different compartments of the tumour microenvironment showed that αMMP9 monotherapy, using AB0046 which only inhibits murine MMP9, resulted in more gene expression changes in the mouse stroma than in the human epithelial tumour compartment, compared to other F I G U R E 2 Qualitative assessment of tumour-associated aspects after therapy with anti-MMP9 antibody and nab-paclitaxel-based chemotherapy. In an AsPC-1 PDAC peritoneal dissemination xenograft study with 2-wk therapy schedule, qualitative assessment of mice in all therapy groups was performed when control mice became moribund including jaundice, amount of ascites, tumour burden in the pancreas, tumour burden in the stomach, total tumour weight, liver metastasis, spleen metastasis and total metastatic burden treatments. In contrast, NPT+Gem+αMMP9 combination therapy resulted in greater numbers of changes in gene expression compared to the other treatments in the tumour compartment ( Figure 6C ).
As in prior experiments, no discernable therapy-related toxicity was observed in the subcutaneous xenograft study during the therapy period as there was no significant change in the mouse bodyweight in all groups ( Figure S1 ).
| D ISCUSS I ON
The hallmarks of pancreatic cancer are an aggressive local growth of tumour into surrounding parenchyma, vascular and other peri- Peritoneal dissemination is a frequent incidence in PDAC, which is associated with a poor prognosis. 34 The peritoneal dissemination animal survival model used in this study can serve as a relevant pre-clinical model of PDAC as it involves the formation of desmoplastic stroma and metastasis to liver and other visceral sites. 35 Although the present study is based on animal experiments using one human failure of early broad-spectrum MMP inhibitors was correlated with a large number of patients with metastatic disease. 12, 13, 25 Recently, anti-MMP9 antibody has also been shown to promote antitumour immunity by activating T cells in the gastric cancer microenvironment. 41 Overall, the present study demonstrates that with an anti-MMP9 antibody, direct enhancement of PDAC cytotoxic therapy is not high but the specific mechanistic footprint of MMP9 inhibition should be explored for its contribution benefit to combinations with antivascular, other antistromal and immune-based therapy.
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